ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
면역학 바이오시밀러 시장 규모는 향후 몇 년 동안 급성장할 것으로 예측됩니다. 2029년에는 CAGR 12.9%로 135억 7,000만 달러에 달할 전망입니다. 이 예측 기간의 성장 배경에는 의료비 절감에 대한 관심 증가, 만성 염증성 질환의 유병률 증가, 신흥국 시장 침투 확대, 규제 당국의 바이오시밀러 의약품 호환성에 대한 지지 증가, 제약사의 투자 증가 등이 있습니다. 이 기간 동안 예상되는 주요 동향으로는 생물학적 제제 제조 기술의 발전, 연구개발 협력 강화, 차세대 바이오시밀러의 출현, 약물 전달 시스템의 혁신, 바이오시밀러 개발에 인공지능 도입 등을 꼽을 수 있습니다.
만성 면역 질환의 유병률 증가는 향후 몇 년 동안 면역학 바이오시밀러 시장의 성장을 견인할 것으로 예측됩니다. 만성면역질환은 면역체계가 체내 조직을 공격하거나 면역체계를 적절히 방어하지 못하는 지속적인 질환입니다. 이러한 증가는 지속적인 치료, 적극적인 관리, 지속적인 건강 관리 지원이 필요한 장기적인 면역 체계 장애를 가진 사람들 증가로 이어지고 있습니다. 면역학 바이오시밀러는 저렴하고 효과적인 대체 치료제를 제공하고, 장기적인 질병 관리를 지원하며, 면역계 기능 장애를 조절하는 필수 치료에 대한 환자의 접근성을 향상시킵니다. 예를 들어, 2024년 6월 호주 정부 기관인 Australian Institute of Health and Welfare는 전신성 자가면역질환인 류마티스 관절염이 2022년 약 514,000명(2.0%)이 앓고 있으며, 유병률은 여성 2.5%, 남성 1.6%라고 보고했습니다. 6%로 보고했습니다. 따라서 만성 면역 질환의 유병률 증가는 면역학 바이오시밀러 시장의 성장을 가속하고 있습니다.
면역학 바이오시밀러 시장의 주요 기업들은 환자들에게 보다 친숙하고 효과적인 치료 옵션을 제공하기 위해 예상 호환성 지정, 보다 안정적인 개량형 제제, 혁신적인 전달 시스템 등 차세대 바이오시밀러 개발에 집중하고 있습니다. 예상 호환성 지정은 바이오시밀러가 처방자의 승인 없이 약국 수준에서 참조 생물학적 제제를 대체할 수 있는 규제 요건을 충족한다는 것을 나타냅니다. 예를 들어, 2025년 2월 스위스에 본사를 둔 제약사 Sandoz Group AG는 심상성 건선, 건선성 관절염, 크론병, 궤양성 대장염 등 만성 자가면역질환 치료를 위한 스텔라라의 바이오시밀러인 Pyzchiva(ustekinumab-ttwe)를 출시 출시하였습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계 성장 분석과 전략 분석 프레임워크
세계의 면역학 바이오시밀러 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 면역학 바이오시밀러 시장 : 성장률 분석
세계의 면역학 바이오시밀러 시장 실적 : 규모와 성장, 2019-2024
세계의 면역학 바이오시밀러 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 면역학 바이오시밀러 : 전체 시장(TAM)
제6장 시장 세분화
세계의 면역학 바이오시밀러 시장 : 약제 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
단일클론항체
융합 단백질
재조합 단백질
인터페론
기타 바이오시밀러 면역 조절제
세계의 면역학 바이오시밀러 시장 : 질환별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
염증성 장질환
관절염
기타 질환
세계의 면역학 바이오시밀러 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 면역학 바이오시밀러 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
홈케어 환경
외래수술센터(ASC)
세계의 면역학 바이오시밀러 시장 : 단일클론항체, 유형별 세분화 : 분석과 예측, 2019-2024, 2024-2029F, 2034F
Anti-Tumor Necrosis Factor Agents
Anti-Interleukin-6 Agents
Anti-Cluster of Differentiation 20 Agents
Anti-Interleukin-12/23 Agents
기타 단일클론항체
세계의 면역학 바이오시밀러 시장 : 융합단백질, 유형별 세분화 : 분석과 예측, 2019-2024, 2024-2029F, 2034F
Etanercept 바이오시밀러
기타 융합단백질 바이오시밀러
세계의 면역학 바이오시밀러 시장 : 재조합 단백질, 유형별 세분화 : 분석과 예측, 2019-2024, 2024-2029F, 2034F
재조합 인간 인슐린
재조합 인간 성장 호르몬
재조합 인간 에리스로포이에틴
기타 재조합 단백질 바이오시밀러
세계의 면역학 바이오시밀러 시장 : 인터페론, 유형별 세분화 : 분석과 예측, 2019-2024, 2024-2029F, 2034F
인터페론 알파
인터페론 베타
인터페론 감마
세계의 면역학 바이오시밀러 시장 : 기타 바이오시밀러 면역조절제, 유형별 세분화 : 분석과 예측, 2019-2024, 2024-2029F, 2034F
인터류킨 억제제
야누스 키나아제 억제제
기타 면역 조절 바이오시밀러
제7장 지역별/국가별 분석
세계의 면역학 바이오시밀러 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 면역학 바이오시밀러 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
면역학 바이오시밀러 시장 : 경쟁 구도
면역학 바이오시밀러 시장 : 기업 개요
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
LG Chem Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Amgen Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Teva Pharmaceutical Industries Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Astellas Pharma Inc.
Sandoz Group AG
Fresenius Kabi AG
Intas Pharmaceuticals Ltd.
Stada Arzneimittel AG
Cipla Ltd.
Kyowa Kirin Co. Ltd.
Dr. Reddy's Laboratories Ltd.
Samsung Bioepis Co. Ltd.
Gedeon Richter Plc
Celltrion Inc.
Biocon Ltd.
Innovent Biologics Inc.
Biocad
Mabion S.A.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
면역학 바이오시밀러 시장(2029년) : 새로운 기회를 제공하는 국가
면역학 바이오시밀러 시장(2029년) : 새로운 기회를 제공하는 부문
면역학 바이오시밀러 시장(2029년) : 성장 전략
시장 동향에 근거한 전략
경쟁 전략
제36장 부록
LSH
영문 목차
영문목차
Immunology biosimilars are biologic drugs that closely resemble already approved original biologics used to treat immune-related conditions, with no meaningful differences in safety, purity, or effectiveness. They offer more cost-effective treatment options for patients with diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, thereby improving access to vital therapies.
The main categories of immunology biosimilars include monoclonal antibodies, fusion proteins, recombinant proteins, interferons, and others. Monoclonal antibodies are lab-engineered molecules that replicate the immune system's ability to combat harmful agents like viruses and bacteria. These biosimilars are used to treat diseases including inflammatory bowel disease, arthritis, and more. Distribution channels consist of hospital pharmacies, retail pharmacies, online pharmacies, among others. The key end users include hospitals, clinics, homecare providers, and ambulatory surgical centers (ASCs).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The immunology biosimilars medicine market research report is one of a series of new reports from The Business Research Company that provides immunology biosimilars medicine market statistics, including the immunology biosimilars medicine industry global market size, regional shares, competitors with the immunology biosimilars medicine market share, detailed immunology biosimilars medicine market segments, market trends, and opportunities, and any further data you may need to thrive in the immunology biosimilars medicine industry. This immunology biosimilars medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The immunology biosimilars market size has grown rapidly in recent years. It will grow from $7.38 billion in 2024 to $8.35 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth during the historic period can be attributed to the rising adoption of biosimilars, growing demand for affordable biologic treatments, increasing prevalence of autoimmune diseases, expanding patient awareness of biosimilar therapies, and enhanced regulatory support for biosimilar approvals.
The immunology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $13.57 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The projected growth in the forecast period can be attributed to an increasing emphasis on lowering healthcare costs, rising prevalence of chronic inflammatory diseases, expanding market penetration in emerging economies, growing regulatory support for biosimilar interchangeability, and heightened investments from pharmaceutical companies. Key trends expected during this time include advancements in biologics manufacturing technologies, strengthened research and development collaborations, the emergence of next-generation biosimilars, innovations in drug delivery systems, and the incorporation of artificial intelligence in biosimilar development.
The rising prevalence of chronic immunological conditions is expected to drive growth in the immunology biosimilars market in the coming years. Chronic immunological conditions are persistent disorders where the immune system either attacks the body's own tissues or fails to defend it properly. This increase is linked to a growing number of people living with long-term immune system disorders that require ongoing treatment, proactive management, and continuous healthcare support. Immunology biosimilars offer affordable and effective treatment alternatives, aiding long-term disease management and improving patient access to essential therapies that regulate immune system dysfunction. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that rheumatoid arthritis-a systemic autoimmune disease, affected approximately 514,000 people (2.0%) in 2022, with prevalence rates of 2.5% among females and 1.6% among males. Hence, the rising incidence of chronic immunological diseases is fueling growth in the immunology biosimilars market.
Leading companies in the immunology biosimilars market are concentrating on next-generation biosimilar developments such as expected interchangeability designations, improved formulations with greater stability, and innovative delivery systems to offer patients more accessible and effective treatment choices. The anticipated interchangeability designation indicates that a biosimilar meets regulatory requirements to be substituted for the reference biologic at the pharmacy level without prescriber approval. For instance, in February 2025, Sandoz Group AG, a pharmaceutical company based in Switzerland, launched Pyzchiva (ustekinumab-ttwe), a biosimilar to Stelara, intended to treat chronic autoimmune diseases including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This launch, in collaboration with Samsung Bioepis Co. Ltd., a biopharmaceutical firm from South Korea, underscores Sandoz's dedication to broadening access to immunology biosimilars by providing a cost-effective, patient-friendly therapy featuring multiple dosing options, extended stability, and the distinctive ability to be re-refrigerated after initial refrigeration.
In November 2022, Biocon Biologics Ltd., an India-based biosimilars company, acquired the global biosimilars business of Viatris Inc. for an undisclosed sum. Through this acquisition, Biocon Biologics aims to become a fully integrated global leader in biosimilars by securing direct commercial access to both advanced and emerging markets, expanding its portfolio with critical immunology assets, and strengthening its capacity to offer affordable biologic medicines to patients worldwide. Viatris Inc. is a US-based healthcare company engaged in developing and commercializing immunology biosimilars.
Major players in the immunology biosimilars market are Pfizer Inc., Novartis AG, LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Stada Arzneimittel AG, Cipla Ltd., Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, and Mabion S.A.
North America was the largest region in the immunology biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunology biosimilars report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the immunology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The immunology biosimilars market consists of sales of tumor necrosis factor inhibitors, recombinant cytokines, t-cell co-stimulation modulators, and monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Immunology Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on immunology biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for immunology biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The immunology biosimilars market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Monoclonal Antibodies; Fusion Proteins; Recombinant Proteins; Interferons; Other Biosimilar Immunomodulators
2) By Disease: Inflammatory Bowel Disease; Arthritis; Other Diseases
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By End User: Hospitals; Clinics; Homecare Settings; Ambulatory Surgical Centers (ASCs)
Subsegments:
1) By Monoclonal Antibodies: Anti-Tumor Necrosis Factor Agents; Anti-Interleukin-6 Agents; Anti-Cluster of Differentiation 20 Agents; Anti-Interleukin-12/23 Agents; Other Monoclonal Antibodies
2) By Fusion Proteins: Etanercept Biosimilars; Other Fusion Protein Biosimilars
3) By Recombinant Proteins: Recombinant Human Insulin; Recombinant Human Growth Hormone; Recombinant Human Erythropoietin; Other Recombinant Protein Biosimilars
4) By Interferons: Interferon Alpha; Interferon Beta; Interferon Gamma
5) By Other Biosimilar Immunomodulators: Interleukin Inhibitors; Janus Kinase Inhibitors; Other Immunomodulatory Biosimilars
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Immunology Biosimilars Market Characteristics
3. Immunology Biosimilars Market Trends And Strategies
4. Immunology Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Immunology Biosimilars Growth Analysis And Strategic Analysis Framework
5.1. Global Immunology Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Immunology Biosimilars Market Growth Rate Analysis
5.4. Global Immunology Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Immunology Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Immunology Biosimilars Total Addressable Market (TAM)
6. Immunology Biosimilars Market Segmentation
6.1. Global Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Fusion Proteins
Recombinant Proteins
Interferons
Other Biosimilar Immunomodulators
6.2. Global Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inflammatory Bowel Disease
Arthritis
Other Diseases
6.3. Global Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Immunology Biosimilars Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Homecare Settings
Ambulatory Surgical Centers (ASCs)
6.5. Global Immunology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Tumor Necrosis Factor Agents
Anti-Interleukin-6 Agents
Anti-Cluster of Differentiation 20 Agents
Anti-Interleukin-12/23 Agents
Other Monoclonal Antibodies
6.6. Global Immunology Biosimilars Market, Sub-Segmentation Of Fusion Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Etanercept Biosimilars
Other Fusion Protein Biosimilars
6.7. Global Immunology Biosimilars Market, Sub-Segmentation Of Recombinant Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Human Insulin
Recombinant Human Growth Hormone
Recombinant Human Erythropoietin
Other Recombinant Protein Biosimilars
6.8. Global Immunology Biosimilars Market, Sub-Segmentation Of Interferons, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interferon Alpha
Interferon Beta
Interferon Gamma
6.9. Global Immunology Biosimilars Market, Sub-Segmentation Of Other Biosimilar Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interleukin Inhibitors
Janus Kinase Inhibitors
Other Immunomodulatory Biosimilars
7. Immunology Biosimilars Market Regional And Country Analysis
7.1. Global Immunology Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Immunology Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Immunology Biosimilars Market
9.1. China Immunology Biosimilars Market Overview
9.2. China Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Immunology Biosimilars Market
10.1. India Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Immunology Biosimilars Market
11.1. Japan Immunology Biosimilars Market Overview
11.2. Japan Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Immunology Biosimilars Market
12.1. Australia Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Immunology Biosimilars Market
13.1. Indonesia Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Immunology Biosimilars Market
14.1. South Korea Immunology Biosimilars Market Overview
14.2. South Korea Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Immunology Biosimilars Market
15.1. Western Europe Immunology Biosimilars Market Overview
15.2. Western Europe Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Immunology Biosimilars Market
16.1. UK Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Immunology Biosimilars Market
17.1. Germany Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Immunology Biosimilars Market
18.1. France Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Immunology Biosimilars Market
19.1. Italy Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Immunology Biosimilars Market
20.1. Spain Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Immunology Biosimilars Market
21.1. Eastern Europe Immunology Biosimilars Market Overview
21.2. Eastern Europe Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Immunology Biosimilars Market
22.1. Russia Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Immunology Biosimilars Market
23.1. North America Immunology Biosimilars Market Overview
23.2. North America Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Immunology Biosimilars Market
24.1. USA Immunology Biosimilars Market Overview
24.2. USA Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Immunology Biosimilars Market
26.1. South America Immunology Biosimilars Market Overview
26.2. South America Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Immunology Biosimilars Market
27.1. Brazil Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Immunology Biosimilars Market
28.1. Middle East Immunology Biosimilars Market Overview
28.2. Middle East Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Immunology Biosimilars Market
29.1. Africa Immunology Biosimilars Market Overview
29.2. Africa Immunology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Immunology Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Immunology Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Immunology Biosimilars Market Competitive Landscape And Company Profiles
